Ipratropium

證據等級: L5

預測適應症: 10 個

Ipratropium: From COPD & Bronchospasm to Obstructive Lung Disease

One-Sentence Summary

Ipratropium (Atrovent®) is a well-established anticholinergic bronchodilator used globally for decades to treat bronchospasm in COPD and asthma, but is currently not registered in the Philippines. The TxGNN model predicts it to be highly effective for Obstructive Lung Disease with a score of 99.97%, backed by multiple completed Phase 3 RCTs — including one conducted specifically in Filipino COPD patients — and 20 supporting publications. This is not a novel repurposing in the traditional sense, but a strong evidence-based case for introducing a proven drug to an underserved market.

Quick Overview

Item	Content
Original Indication	COPD / Bronchospasm (established globally; no Philippines registration on file)
Predicted New Indication	Obstructive Lung Disease
TxGNN Prediction Score	99.97%
Evidence Level	L1
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ipratropium competitively antagonizes muscarinic M3 receptors on bronchial smooth muscle, blocking vagally-mediated bronchoconstriction and producing sustained bronchodilation. It also inhibits M1/M3 receptors on submucosal glands, reducing pathological airway hypersecretion. This dual mechanism directly addresses the core pathophysiology of obstructive lung disease: excessive parasympathetic airway tone, dynamic airflow limitation, and mucus plugging — all hallmarks of COPD and related conditions.

Obstructive lung disease encompasses conditions — most prominently COPD — where persistent airflow limitation arises from both bronchospasm and structural airway remodeling. Because the cholinergic pathway is the dominant bronchomotor tone in human airways, M3 receptor antagonism provides a mechanistically targeted and predictable therapeutic effect. This is why ipratropium remains a cornerstone in global COPD guidelines (GOLD) and has been used clinically since the 1980s.

The TxGNN prediction is therefore a high-confidence confirmation from the knowledge graph rather than a speculative leap. Particularly notable is that one of the pivotal Phase 3 trials (NCT02172469) was conducted specifically in Filipino patients with COPD, providing direct population-level evidence for this exact clinical context.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00000568	Phase 3	Completed	N/A	Landmark Lung Health Study I & III: directly evaluated ipratropium’s effect on FEV1 decline rate and cardiopulmonary morbidity/mortality in early COPD — highest-level direct evidence for this indication
NCT02172469	Phase 3	Completed	215	Tiotropium vs Atrovent® MDI specifically in Filipino COPD patients — directly establishes ipratropium efficacy and safety benchmark in the Philippine population
NCT02233881	N/A	Completed	4,222	Large post-marketing surveillance of Atrovent® inhalets (n=4,222): real-world tolerability and efficacy in COPD daily practice
NCT00846586	Phase 3	Completed	1,134	Double-blind RCT: indacaterol + tiotropium vs tiotropium alone in moderate-to-severe COPD; high-quality direct evidence for anticholinergic class
NCT00400153	Phase 3	Completed	1,480	Combivent Respimat (ipratropium/salbutamol) vs COMBIVENT® MDI: demonstrated non-inferiority on FEV1 AUC over 12 weeks in COPD
NCT01019694	Phase 3	Completed	470	Long-term safety and patient acceptability of Combivent Respimat vs Atrovent HFA in COPD; confirmed favorable long-term safety profile
NCT02182713	Phase 4	Completed	30	Combivent (ipratropium + salbutamol) vs salbutamol alone against methacholine-induced bronchoconstriction: ipratropium combination confers additional protection
NCT02182700	Phase 3	Terminated	47	Combivent aerosol + spacer in moderate-to-severe asthma crisis in ER; early termination limits interpretation, but directly involves ipratropium
NCT02236715	N/A	Completed	1,039	Post-marketing surveillance of Atrovent® Unit Dose Vial 500 µg in chronic obstructive airways disease: confirmed real-world tolerability
NCT00274040	Phase 3	Completed	141	Tiotropium vs ipratropium MDI in COPD: ipratropium (Atrovent) used as active comparator, providing direct bronchodilator efficacy data

Literature Evidence

PMID	Year	Type	Journal	Key Findings
26391969	2015	Cochrane Meta-analysis	Cochrane Database Syst Rev	Tiotropium vs ipratropium in stable COPD: tiotropium superior on FEV1, QoL, and exacerbations — confirms ipratropium as established active comparator with proven efficacy
24043433	2013	Cochrane Meta-analysis	Cochrane Database Syst Rev	Earlier Cochrane head-to-head comparison; ipratropium established as effective COPD treatment baseline
16856113	2006	Cochrane Meta-analysis	Cochrane Database Syst Rev	Ipratropium vs LABAs for stable COPD: ipratropium effective bronchodilator with comparable symptom relief and favorable safety profile
20163324	2010	Systematic Review	Expert Opin Drug Metab Toxicol	Reviews mechanism, clinical efficacy, and safety of albuterol, ipratropium, and combination therapy in COPD; combination approved >15 years prior to publication
38457591	2024	RCT	Medicine	Probiotics + budesonide + ipratropium in COPD (n=118): combination improves lung function and gut microbiota vs budesonide + ipratropium alone — recent real-world evidence
8181328	1994	RCT	Chest	85-day multicenter trial (COMBIVENT Study Group): ipratropium + albuterol combination more effective than either agent alone in COPD
7813271	1995	RCT	Chest	Pirbuterol vs ipratropium in COPD: differential effects on gas exchange and ventilation distribution — ipratropium uniquely preserves V/Q matching
23170031	2012	Clinical Study	Ann Pharmacother	Evidence review of concomitant ipratropium + tiotropium in COPD: additive bronchodilation with acceptable safety
2977109	1988	Review	Clinical Pharmacy	Comprehensive review of ipratropium pharmacology, kinetics, and clinical efficacy in obstructive lung disease; foundational reference
6448137	1980	Pharmacological Review	Drugs	Seminal characterization of ipratropium bromide: anticholinergic bronchodilator at least as effective as beta-2 agonists in chronic bronchitis

Philippines Market Information

Ipratropium currently has no active drug authorizations in the Philippines (0 registered products). The drug is widely approved in other major markets under brand names including Atrovent® (inhaler and unit-dose nebules) and Combivent® (combination with salbutamol).

This absence represents a clear regulatory gap given the high COPD burden in the Philippines and the availability of L1-level evidence including a dedicated Filipino patient cohort study.

Safety Considerations

Full Philippines FDA package insert data (key warnings, contraindications) was not available in the current evidence pack.

Please refer to the originator package insert for complete safety information. Based on the drug’s well-characterized pharmacological class (quaternary ammonium anticholinergic), clinicians should be aware of anticholinergic class effects including risk of acute angle-closure glaucoma (particularly with nebulized formulation and eye exposure), urinary retention in patients with benign prostatic hyperplasia, and paradoxical bronchospasm. No drug interaction data was retrieved from the DDI database for this submission.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Ipratropium meets L1 evidence criteria with multiple completed Phase 3 RCTs for obstructive lung disease — including a trial conducted in Filipino COPD patients — and a 99.97% TxGNN prediction score, making it one of the strongest repurposing candidates in this pipeline. The primary barrier to deployment is the absence of Philippines regulatory registration, not a lack of efficacy evidence.

To proceed, the following is needed:

Submit Philippines FDA (FDA-PH) registration dossier, leveraging existing FDA USA / EMA approvals via abridged or mutual recognition pathway
Obtain and translate full originator package insert (key warnings, contraindications, drug interactions) for Philippines labeling compliance
Confirm supply chain and cold-chain logistics for inhaler formulations in the local distribution network
Conduct pharmacoeconomic analysis for formulary inclusion (PhilHealth Essential Medicines List, DOH formulary)
Establish post-marketing pharmacovigilance plan specific to the Philippine patient population
Review NCT02172469 full dataset to extract Filipino-specific subgroup safety and efficacy data for the registration submission
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.